Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Post by
Pronorvista
on Apr 18, 2023 2:12pm
Ate
En tant qu'entrepreneur et investisseur en srie, Yung a cr des entreprises rvolutionnaires grande chelle dans les domaines des logiciels d'entreprise, de l'analyse mobile et du big data
...more
(8)
•••
TechMoose
X
View Profile
View Bullboard History
Post by
TechMoose
on Apr 18, 2023 1:34pm
Antibe Director to Leave Position (As CEO of MaRS)
Call me an eternal optimist, but I am wondering if Yung Wu's upcoming departure may open up a window for Antibe to step out more and drive visibility. He's a proven operator. Smart
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 18, 2023 7:04am
New Press Release - Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in...
read article.
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Apr 17, 2023 9:33am
This could be us (down the road) Bayer to buy ATE lol
Merck said on Sunday it will buy Prometheus Biosciences for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn’s disease and building up
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Apr 16, 2023 3:41pm
RE:RE:ATE
I agree that the last update was a nothing-burger but it did tell us a few things. 1. Acute across the finish line is priority #1. 2. DILIsym is now being used to get preliminary
...more
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Apr 15, 2023 8:39am
RE:ATE
There's nothing to talk about here. Their latest update was without anything of substance. Still holding. I think there is upside but Im not accumulating anymore. I&
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Apr 14, 2023 8:26pm
RE:ATE
Quietly accumulating. I'm here !
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Post by
Pronorvista
on Apr 12, 2023 1:46pm
ATE
Only 13k volume today
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Post by
Pronorvista
on Apr 12, 2023 1:44pm
ATE
the believers are all gone ???
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Comment by
Inthepez
on Apr 12, 2023 11:11am
RE:Good Update
nice to see dumpster on his best behaviour. Glad you finally got the help you needed.
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Apr 11, 2023 12:53pm
Good Update
lots going on with the company. chronic pain still in play for otena. progress on (IBD) next update end of june for patent application filing and a announcement on anti-inflamatory compounds that are
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 11, 2023 7:05am
New Press Release - Antibe Provides April 2023 Corporate Update
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formulation...
read article.
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Apr 05, 2023 8:05pm
RE:i am surprised
Ya - people are unaware and uninterested at this time. All good ! I'm not one for fanfare anyway. Financials are likely out around June 28th. That's also likely the time that we get a
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Apr 05, 2023 1:12pm
i am surprised
we are not geting bid up today. we usually do on days like today. this is a safe and defensive place to park some cash. and doubly so when news could come out at anytime. maybe cause we no longer have
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Mar 31, 2023 10:11pm
RE:RE:Q2 - 2023 Milestones
Yes - I think we've seen delays since last Q2 w.r.t. IBD. I think it all relates to proving that there isn't an ROS issue. Watching closely for the details around IBD and why they expect
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >